Literature DB >> 26688112

Patient-relevant treatment goals in psoriasis.

Christine Blome1, Ramona Gosau2, Marc A Radtke2, Kristian Reich3, Stephan J Rustenbach2, Christina Spehr2, Diamant Thaçi4, Matthias Augustin2.   

Abstract

Patient-oriented care requires therapeutic decisions to agree with the patients' treatment needs and goals. This study addressed the following questions: What is important to psoriasis patients starting systemic treatment? How stable are these preferences within the first year of treatment? Are treatment goals associated with age, gender, or treatment success? The importance of treatment goals was assessed for patients with moderate-to-severe psoriasis in the German Psoriasis Registry (PsoBest) at baseline (onset of a systemic treatment; n = 3066) and at a 1-year follow-up (n = 1444) using the Patient Benefit Index (PBI). Treatment success was measured with PBI global score and Psoriasis Area Severity Index (PASI). Patients with moderate-to-severe psoriasis pursued a wide range of different goals. The most general treatment goals were rated most relevant, including skin healing and quick skin improvement (94.8/94.5 % "quite" or "very" important), confidence in the therapy (93.0 %), control over the disease (92.3 %), and a clear diagnosis and therapy (89.6 %). Further important goals related to not being in fear of the disease getting worse (84.8 %), reduction in itching (83.9 %), burning (70.6 %), and pain (60.6 %) as well as attaining a normal everyday life (78.4 %) and low treatment burden (64.2-77.9 %). Goals were mostly not associated with sex and gender. Goal importance slightly increased with treatment success. In a substantial proportion of patients (30.3-54.7 %) goal importance changed within 1 year after onset of systemic treatment. We conclude that treatment goal importance should be assessed in clinical practice on a regular basis.

Entities:  

Keywords:  Health-related quality of life; Patient Benefit Index; Patient preferences; Psoriasis; Treatment goals

Mesh:

Year:  2015        PMID: 26688112     DOI: 10.1007/s00403-015-1613-8

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

Review 2.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 3.  Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study.

Authors:  Luis Puig; Baojin Zhu; Russel Burge; David Shrom; Yan Dong; Wei Shen; Lotus Mallbris; Kristian Reich
Journal:  J Clin Aesthet Dermatol       Date:  2020-10-01

4.  Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab.

Authors:  Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong
Journal:  Drugs Real World Outcomes       Date:  2021-03-28

5.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.

Authors:  Melodie Young; Heather L Roebuck
Journal:  J Am Assoc Nurse Pract       Date:  2016-11-21       Impact factor: 1.165

Review 6.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

7.  Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

Authors:  A Blauvelt; K Reich; S Mehlis; F Vanaclocha; H Sofen; W Abramovits; Y Zhao; I Gilloteau; E Davenport; N Williams; A Guana; S Tyring
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-08-08       Impact factor: 6.166

Review 8.  The German National Program on Psoriasis Health Care 2005-2015: results and experiences.

Authors:  M Augustin; L Eissing; A Langenbruch; A Enk; T Luger; D Maaßen; U Mrowietz; K Reich; M Reusch; K Strömer; D Thaçi; R von Kiedrowski; M A Radtke
Journal:  Arch Dermatol Res       Date:  2016-04-05       Impact factor: 3.017

9.  Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention.

Authors:  Jördis Maria Zill; Jörg Dirmaier; Martin Härter; Ulrich Mrowietz; Matthias Augustin; Sarah Dwinger; Eva Christalle
Journal:  JMIR Res Protoc       Date:  2018-02-07

10.  Measuring the importance of health domains in psoriasis - discrete choice experiment versus rating scales.

Authors:  Mandy Gutknecht; Marthe-Lisa Schaarschmidt; Marion Danner; Christine Blome; Matthias Augustin
Journal:  Patient Prefer Adherence       Date:  2018-03-15       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.